The fine line between abuse and fair use at the PTAB
Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system
Roughly 700 Patent Trial and Appeal Board (PTAB) petitions had been filed in 2015 by May 20. Yet the story attracting the most interest for PTAB observers this year concerns a mere 2% of these.
Kyle Bass, who owns Dallas-based...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.